Table A4.
Clinical Characteristics by RS Among Patients With ER-Positive/HER2-Negative De Novo Stage IV Breast Cancer
| RS Risk Group, No. (%) | ||||
|---|---|---|---|---|
| Low Risk (RS < 18) | Intermediate Risk (RS 18-30) | High Risk (RS ≥ 31) | P | |
| No. of patients | 22 | 26 | 21 | |
| Median age, years (range) | 58 (38-73) | 52 (26-79) | 50 (21-77) | .246 |
| Median tumor size, cm (range) | 2.6 (0.8-9) | 3.1 (0.7-15) | 3.5 (1-9) | .352 |
| ECOG status | .651 | |||
| 0 | 9 (41) | 16 (62) | 11 (52) | |
| > 0 | 13 (59) | 10 (38) | 10 (48) | |
| Cohort | .001 | |||
| A | 20 (91) | 19 (73) | 21 (100) | |
| B | 2 (9) | 7 (27) | 0 (0) | |
| Site of first metastasis | .397 | |||
| Bone | 14 (64) | 14 (54) | 10 (48) | |
| Visceral | 5 (23) | 6 (23) | 3 (14) | |
| Both | 2 (9) | 4 (15) | 7 (33) | |
| Other* | 1 (4) | 2 (8) | 1 (5) | |
| No. of metastases | .580 | |||
| 1 | 16 (73) | 16 (62) | 11 (52) | |
| > 1 | 6 (27) | 10 (38) | 10 (48) | |
| Tumor grade† | ||||
| I | 5 (23) | 0 (0) | 1 (5) | < .001 |
| II | 15 (68) | 11 (52) | 3 (15) | |
| III | 2 (9) | 10 (48) | 16 (80) | |
Abbreviations: ER, estrogen receptor; ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal growth factor receptor 2; RS, Recurrence Score.
*
Includes mediastinal lymph nodes, endobronchial lymph nodes, skin, and pleura.
†
Locally reported tumor grade missing for five patients in the intermediate-risk group and one patient in the high-risk group.